Division of Nephrology, Keck School of Medicine, University of Southern California, 2020 Zonal Avenue, Los Angeles, CA 90033, USA.
J Nephrol. 2011 Sep-Oct;24(5):550-3. doi: 10.5301/jn.5000024.
Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.
已有多项综述探讨了血脂异常在肾脏损伤中的作用，以及 3-羟基-3-甲基戊二酰辅酶 A（HMG-CoA）还原酶抑制剂（他汀类药物）的潜在肾脏保护作用。动物实验证据有力地支持了他汀类药物可能具有肾脏保护作用的观点。然而，人类的数据却很少且相互矛盾。最近一项使用罗苏伐他汀的对照研究对该药物的肾脏保护作用提出了一些质疑。本文综述了现有的证据，包括他汀类药物在人类受试者中的肾脏保护作用的正反两方面。
